• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 15, 2014

View Archived Issues

ASCO highlights promising treatments and nontreatments

This year the American Society of Clinical Oncology (ASCO) is holding its meeting for the 50th time. At a press conference preceding the release of abstracts yesterday, ASCO president Clifford Hudis took a moment to celebrate some of the more impressive victories that clinical oncology has collectively achieved over the past few decades. Read More

BMS, Celldex team up; Incyte, Medi say 'I do' for checkpoint trials

The already-bright hope for Bristol-Myers Squibb Co.'s (BMS) PD-1 checkpoint inhibitor nivolumab in non-small-cell lung cancer (NSCLC) was bolstered by a deal to test the compound with Celldex Therapeutics Inc.'s CD27-targeting varlilumab, on a day that saw another oncology deal in the same space between Incyte Corp. and Medimmune, part of London-based Astrazeneca plc. Read More

Isis investors find hope in positive phase II diabetes data

Isis Pharmaceuticals Inc. shares (NASDAQ:ISIS) extended a slow recovery Wednesday as investors took note of phase II data showing that the company's experimental antisense drug, ISIS-GCGRRx, helped patients with type 2 diabetes improve control of the disease, even when they're unable to do so with metformin. Read More

CFDA drafts drug law aimed at flushing out regulatory bottlenecks

SHANGHAI – At the 6th DIA Annual Meeting here this week, many of the 1,500 attendees are justifiably concerned about how to get medicines into the hands of those who need it most in China faster and more efficiently, where drugs hit the market several years after the U.S. or EU. Read More

Round II: More questions are raised on Pfizer's commitment to UK R&D

LONDON – "Welcome back for round two," said Andrew Miller MP, chair of the science and technology committee, opening the second parliamentary hearing in as many days on Pfizer Inc.'s proposed takeover of Astrazeneca plc. Read More

Exiting ophthalmic market, Merck signs $600M+ Santen deal

HONG KONG – Merck & Co. Inc. has signed a deal to sell nine of its ophthalmic products to Japan-based Santen Pharmaceutical Co. Ltd. The decision to spin off the products to its long-time partner is Merck's latest move out of the ophthalmic market. Read More

Washington roundup

The Patent and Trademark Office (PTO) finalized an interim rule implementing the 14-month and three-year patent term adjustment provisions of the America Invents Act Technical Corrections Act. Read More

Stock movers

Read More

Other news to note

Hemispherx Biopharma Inc., of Philadelphia, said it entered a formal research agreement to test Alferon N injection, a multispecies, natural alpha interferon, against wild-type and Tamiflu (oseltamivir, Roche AG)-resistant H7N9 influenza virus under the Data Exchange Agreement Annex for Medical Preparedness and Bio-Defense Agreement between the Swiss Surgeon General and the U.S. Department of Defense. Read More

Pharma: Other news to note

Pernix Therapeutics Holdings Inc., of Morristown, N.J., said it signed an agreement with Glaxosmithkline plc, of London, to acquire the U.S. rights to Treximet (sumatriptan/naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Read More

Clinic roundup

Amgen, of Thousand Oaks, Calif., said data from the phase III LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) study were published in the Journal of the American Medical Association. Read More

Pharma: Clinic roundup

Astellas Pharma US Inc., of Northbrook, Ill., part of Astellas Pharma Inc., reported that efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe